Sight Sciences’ OMNI Surgical System is the only dually FDA-indicated device to deposit viscoelastic in the anterior segment and to perform a trabeculotomy. The OMNI Surgical System is the result of customer feedback and a desire to have a treatment option designed to target potential areas of resistance in the conventional outflow pathway.

“We are excited to bring the OMNI Surgical System to market as the next evolution in our surgical portfolio,” says Shawn O’Neil, chief commercial officer of Sight Sciences in Menlo Park, California. “OMNI is the result of customers informing us that the surgeon wants the best chance to access the conventional outflow pathway, and obsessive engineering to make that a reality in a single device.”

The OMNI device is designed to allow the surgeon to deliver viscoelastic where desired into the anterior segment. The surgeon can also insert the OMNI catheter into the Schlemm canal to perform a controlled trabeculotomy that can be customized up to 360 degrees.

Benefits Abound

Steven R. Sarkisian, Jr., MD, glaucoma fellowship director at the Dean McGee Eye Institute and clinical professor in the Department of Ophthalmology at the University of Oklahoma College of Medicine, both in Oklahoma City, Oklahoma, can attest to the tool’s versatility. Dr. Sarkisian’s center is a tertiary referral center and he has used the OMNI device in a variety of patients.

Dr. Sarkisian has found many advantages to using the device. “It only requires 1 incision rather than the traditional 2 or 3 that other devices require,” he says. “The width of the nylon probe used for goniotomy or trabeculotomy does not simply cut through trabecular meshwork, it also does a good job at removing it.”

Unlike other techniques that can only be used to do a partial trabeculotomy of approximately 100 to 140 degrees, OMNI does a full 360-degree goniotomy. The OMNI has improved upon its predecessors — Sight Sciences’ VISCO360 and TRAB360. “The motion of the spinning wheel is much smoother and more efficient,” Dr. Sarkisian says. “The mechanism of action inside the device handle that controls the probe is an advanced feat of engineering, considering that it allows the probe to be retracted four to five times, with two of those retractions causing injection of viscoelastic.”

User Friendly

The OMNI has demonstrated a reasonable learning curve for surgeons familiar with performing angle procedures, such as minimally invasive glaucoma surgery, O’Neil says. It was designed to make invasive and challenging procedures more efficient and reproducible for both glaucoma and anterior-segment surgeons.

Dr. Sarkisian says the tool fits different hand sizes comfortably, and it performs reliably and consistently. Moreover, filling the device with viscoelastic is easy to do. Only one incision is required and the tip’s curvature is just right to enter the canal. “The surgeon powers the injection of viscoelastic rather than an assistant, giving the surgeon full control during the entire surgery,” he says. GP